血清阳性临床可疑关节痛中扩增的血液PD-1hi Tfh细胞可预测类风湿关节炎进展
该前瞻性非干预研究评估了临床可疑关节痛(CSA)患者外周血循环Tfh(cTfh)和Tph(cTph)细胞频率。结果显示血清阳性CSA患者cTfh和cTph扩增,且cTfh频率>0.66%可预测进展为类风湿关节炎(敏感性72%,特异性85%)。
要点
- 血清阳性CSA患者基线cTfh和cTph频率较健康对照扩增。
- 血清阳性CSA中进展为RA者基线cTfh和cTph频率高于未进展者。
- cTfh频率>0.66%可预测进展为RA,敏感性72%、特异性85%。
核心结论
- 血清阳性CSA患者基线cTfh和cTph频率升高,较高cTfh比例与进展为RA相关。
研究设计与样本
- 前瞻性非干预研究,基线采集CSA患者和年龄性别匹配健康对照的外周血,流式细胞术分析PBMCs,随访至RA发病或最长48个月。
主要发现
- 与健康对照相比,血清阳性CSA患者(RF和/或ACPA+,n=33)cTfh和cTph频率扩增,而血清阴性CSA患者(n=37)无此表现。
- 血清阳性CSA中进展为RA者基线cTfh和cTph频率高于未进展者。
- cTfh频率>0.66%预测进展,敏感性72%,特异性85%。
- RA发病时,血清阳性进展者(n=19)cTph频率进一步升高,而cTfh频率无进一步升高。
关键数值与推荐
- cTfh频率>0.66%作为预测进展为RA的阈值,敏感性72%,特异性85%。
临床怎么用
- cTfh和cTph profiling可用于对血清阳性CSA个体进行进展风险分层,辅助早期治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Individuals with clinically suspect arthralgia (CSA, EULAR definition) are at increased risk of developing rheumatoid arthritis (RA) and early therapeutic intervention may delay or prevent progression. However, improved identification of likely progressors is needed to avoid unnecessary treatment. CD4+CXCR5+PD-1hi follicular helper (Tfh) and CD4+CXCR5-PD-1hi peripheral helper (Tph) T cells are implicated in RA pathogenesis. Notably, Tfh associate with favourable responses to co-stimulation blockade. Profiling these subsets in CSA could enhance our understanding of the RA preclinical phase, help identify progressors and select targeted therapies. Our objective was to assess circulating Tfh (cTfh) and Tph (cTph) cell frequencies in CSA. METHODS: In this prospective, non-interventional study, peripheral blood was collected at baseline from CSA patients and age- and gender-matched healthy controls (HC). PBMCs were isolated and analysed by flow cytometry. Patients were followed until RA onset or for up to 48 months. RESULTS: Compared with HC, seropositive CSA (RF and/or ACPA+, n = 33), but not seronegative CSA patients (n = 37), demonstrated expanded frequencies of cTfh and cTph cells. Among seropositive CSA patients, those who progressed to RA had higher baseline cTfh and cTph frequencies than non-progressors. A cTfh frequency >0.66% predicted progression (sensitivity 72%, specificity 85%). At RA onset, seropositive progressors (n = 19) showed a further increase in cTph, but not cTfh, frequency. CONCLUSION: Seropositive CSA patients display elevated baseline cTfh and cTph frequencies. Higher cTfh proportions associate with progression to RA. These findings support the use of cTfh and cTph profiling to stratify progression risk and guide early therapeutic decisions in at-risk individuals.
引用
- Nuño L, Nieto-Carvalhal B, Gutiérrez-Riart M, et al. Expanded blood PD-1hi Tfh cells in seropositive clinically suspect arthralgia predict progression to rheumatoid arthritis. Rheumatology (Oxford). 2026. PMID: 41346250. doi:10.1093/rheumatology/keaf648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。